AU2005221403B8 - Stabilised supersaturated solid solutions of steroidal drugs - Google Patents

Stabilised supersaturated solid solutions of steroidal drugs Download PDF

Info

Publication number
AU2005221403B8
AU2005221403B8 AU2005221403A AU2005221403A AU2005221403B8 AU 2005221403 B8 AU2005221403 B8 AU 2005221403B8 AU 2005221403 A AU2005221403 A AU 2005221403A AU 2005221403 A AU2005221403 A AU 2005221403A AU 2005221403 B8 AU2005221403 B8 AU 2005221403B8
Authority
AU
Australia
Prior art keywords
solvent
steroidal molecule
steroidal
composition
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005221403A
Other languages
English (en)
Other versions
AU2005221403B2 (en
AU2005221403A1 (en
Inventor
Adrian Funke
Ralph Lipp
Torsten Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005221403(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of AU2005221403A1 publication Critical patent/AU2005221403A1/en
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Alteration of Name(s) of Applicant(s) under S113 Assignors: SCHERING AKTIENGESELLSCHAFT
Publication of AU2005221403B2 publication Critical patent/AU2005221403B2/en
Application granted granted Critical
Publication of AU2005221403B8 publication Critical patent/AU2005221403B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AU2005221403A 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs Ceased AU2005221403B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
EP04075714.8 2004-03-10
US60/551,330 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (3)

Publication Number Publication Date
AU2005221403A1 AU2005221403A1 (en) 2005-09-22
AU2005221403B2 AU2005221403B2 (en) 2009-12-10
AU2005221403B8 true AU2005221403B8 (en) 2010-01-07

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005221403A Ceased AU2005221403B8 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Country Status (32)

Country Link
US (1) US8715735B2 (cg-RX-API-DMAC7.html)
EP (2) EP2087883B1 (cg-RX-API-DMAC7.html)
JP (1) JP5006185B2 (cg-RX-API-DMAC7.html)
KR (1) KR101210695B1 (cg-RX-API-DMAC7.html)
CN (1) CN1984644B (cg-RX-API-DMAC7.html)
AR (1) AR048500A1 (cg-RX-API-DMAC7.html)
AT (1) ATE442131T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005221403B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507342A (cg-RX-API-DMAC7.html)
CA (1) CA2558582C (cg-RX-API-DMAC7.html)
CR (1) CR8630A (cg-RX-API-DMAC7.html)
DE (1) DE602005016551D1 (cg-RX-API-DMAC7.html)
DK (1) DK1765290T3 (cg-RX-API-DMAC7.html)
EA (1) EA012746B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066902A (cg-RX-API-DMAC7.html)
ES (2) ES2390406T3 (cg-RX-API-DMAC7.html)
GT (1) GT200500045A (cg-RX-API-DMAC7.html)
HR (1) HRP20090614T1 (cg-RX-API-DMAC7.html)
IL (1) IL177894A0 (cg-RX-API-DMAC7.html)
MY (1) MY142989A (cg-RX-API-DMAC7.html)
NO (1) NO20064473L (cg-RX-API-DMAC7.html)
NZ (1) NZ549793A (cg-RX-API-DMAC7.html)
PA (1) PA8626101A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060016A1 (cg-RX-API-DMAC7.html)
PL (1) PL1765290T3 (cg-RX-API-DMAC7.html)
PT (1) PT1765290E (cg-RX-API-DMAC7.html)
RS (1) RS51076B (cg-RX-API-DMAC7.html)
SI (1) SI1765290T1 (cg-RX-API-DMAC7.html)
SV (1) SV2005002044A (cg-RX-API-DMAC7.html)
TW (1) TWI345986B (cg-RX-API-DMAC7.html)
UY (1) UY28803A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005087199A2 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
CN101232869B (zh) * 2005-06-16 2016-03-02 沃纳奇尔科特有限责任公司 局部给药的凝胶组合物
CA2612380C (en) * 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
EP2023899A1 (en) * 2006-05-10 2009-02-18 Evonik Degussa GmbH Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US20100119601A1 (en) * 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
CA2714340A1 (en) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
JP5437232B2 (ja) * 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
US8288342B2 (en) * 2008-10-10 2012-10-16 Teva Women's Health, Inc. Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
CA2752805A1 (en) * 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
CA2992923C (en) 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
EP3582626B1 (en) * 2017-02-14 2021-09-15 DSM IP Assets B.V. Water dispersible formulations
CN121220615A (zh) * 2017-02-14 2025-12-30 帝斯曼知识产权资产管理有限公司 贮存稳定的配制物
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP7847966B2 (ja) * 2020-10-23 2026-04-20 富士製薬工業株式会社 医薬製剤およびその製造方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1365661A (en) * 1972-02-03 1974-09-04 Liebenberg R W Prparation of medicinal and food compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
US4254099A (en) * 1978-10-18 1981-03-03 Beiersdorf Aktiengesellschaft Pharmaceutical tablet composition
EP0336014A1 (en) * 1988-04-08 1989-10-11 VECTORPHARMA INTERNATIONAL S.p.A. Pharmaceutical compositions with controlled release, and a method for their preparation
US20030054037A1 (en) * 2001-06-22 2003-03-20 Babcock Walter C. Pharmaceutical compositions of adsorbates of amorphous drug
WO2004073689A1 (en) * 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
ES2062634T3 (es) 1990-08-30 1994-12-16 Senju Pharma Co Composicion con liberacion controlada del farmaco.
DK0492007T3 (da) * 1990-11-29 1995-06-26 Faulding F H & Co Ltd Fremgangsmåde til fremstilling af væskepåfyldte pulvere
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
DK1380301T3 (da) 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
AU2001225413B2 (en) 2000-01-18 2005-06-23 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
CN101785775B (zh) 2002-09-05 2015-03-25 潘塔希生物科学股份有限公司 15-或16-位取代的睾酮类似物的药物学应用
WO2004041289A1 (en) 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1365661A (en) * 1972-02-03 1974-09-04 Liebenberg R W Prparation of medicinal and food compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
US4254099A (en) * 1978-10-18 1981-03-03 Beiersdorf Aktiengesellschaft Pharmaceutical tablet composition
EP0336014A1 (en) * 1988-04-08 1989-10-11 VECTORPHARMA INTERNATIONAL S.p.A. Pharmaceutical compositions with controlled release, and a method for their preparation
US20030054037A1 (en) * 2001-06-22 2003-03-20 Babcock Walter C. Pharmaceutical compositions of adsorbates of amorphous drug
WO2004073689A1 (en) * 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Aerosil ? - Internet presentation - Entry no. 5 - Dry Binder: A New Concept for Pressed Powders" [Online] Retrieved 14 December 2003 *
CHOWDARY K P R et al., Indian Journal of Pharmaceutical Sciences, March 2001, vol. 63, pp 150-154 *
MONKHOUSE D C et al., Journal of Pharmaceutical Sciences: American Pharmaceutical Association, September 1972, vol. 61, no. 9, pp 1430-1435 *
NAKAGAMI H., Chemical and Pharmaceutical Bulletin, September 1991, vol. 39, no. 9, pp 2417-2421 *
TAKEUCHI H et al., Chemical and Pharmaceutical Bulletin, 1987, vol. 35, no. 9, pp 3800-3806 *
WATANABE T et al., International Journal of Pharmaceutics, 2001, vol. 226, pp 81-91 *
WATANABE T et al., International Journal of Pharmaceutics, 2002, vol. 248, pp 123-129 *

Also Published As

Publication number Publication date
ES2332229T3 (es) 2010-01-29
US8715735B2 (en) 2014-05-06
US20050207990A1 (en) 2005-09-22
AU2005221403B2 (en) 2009-12-10
PA8626101A1 (es) 2006-07-03
NO20064473L (no) 2006-10-10
JP5006185B2 (ja) 2012-08-22
NZ549793A (en) 2010-06-25
CN1984644A (zh) 2007-06-20
EP1765290B1 (en) 2009-09-09
WO2005087199A2 (en) 2005-09-22
CN1984644B (zh) 2010-12-08
EP2087883A1 (en) 2009-08-12
PE20060016A1 (es) 2006-02-16
JP2007528389A (ja) 2007-10-11
EA012746B1 (ru) 2009-12-30
CR8630A (es) 2007-06-06
SV2005002044A (es) 2005-11-04
WO2005087199A8 (en) 2007-03-29
BRPI0507342A (pt) 2007-07-03
IL177894A0 (en) 2006-12-31
RS51076B (sr) 2010-10-31
CA2558582A1 (en) 2005-09-22
PL1765290T3 (pl) 2010-02-26
PT1765290E (pt) 2009-11-23
ECSP066902A (es) 2006-12-20
DE602005016551D1 (de) 2009-10-22
DK1765290T3 (da) 2009-11-02
GT200500045A (es) 2005-10-31
HRP20090614T1 (hr) 2009-12-31
EP2087883B1 (en) 2012-07-25
EP1765290A2 (en) 2007-03-28
KR101210695B1 (ko) 2012-12-11
AU2005221403A1 (en) 2005-09-22
WO2005087199A3 (en) 2009-01-15
SI1765290T1 (sl) 2010-01-29
HK1103660A1 (en) 2007-12-28
UY28803A1 (es) 2005-10-31
ES2390406T3 (es) 2012-11-12
TW200600116A (en) 2006-01-01
EA200601588A1 (ru) 2007-02-27
ATE442131T1 (de) 2009-09-15
TWI345986B (en) 2011-08-01
AR048500A1 (es) 2006-05-03
CA2558582C (en) 2013-07-16
MY142989A (en) 2011-02-14
KR20060132999A (ko) 2006-12-22

Similar Documents

Publication Publication Date Title
AU2005221403B2 (en) Stabilised supersaturated solid solutions of steroidal drugs
EP1980242B1 (en) Liquid compositions as a micro-emulsion pre-concentrate comprising drospirenone moleculary dispersed
US20050220825A1 (en) Molecular dispersions of drospirenone
CA2691752A1 (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
MXPA06010256A (en) Stabilised supersaturated solids of lipophilic drugs
JP2008518895A (ja) 低用量のエストラジオールを含む経口固形製剤
HK1103660B (en) Stabilised supersaturated solids of lipophilic drugs
TW200840587A (en) Molecular dispersions of drospirenone
MXPA06010254A (es) Composiciones que comprenden drospirenona dispersada a nivel molecular
HK1105116A (en) Compositions comprising drospirenone molecularly dispersed
HK1111087A (en) Oral solid dosage forms containing a low dose of estradiol

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS FROM 14075714.8 10 MAR 2004 EP TO 04075714.8 10 MAR 2004 EP

TH Corrigenda

Free format text: IN VOL 23, NO 48, PAGE(S) 11460 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAMEBAYER SCHERING PHARMA AKTIENGESELLSCHAFT, APPLICATION NO. 2005221403, UNDER INID (54), CORRECT THE TITLE TO READ STABILISED SUPERSATURATED SOLID SOLUTIONS OF STEROIDAL DRUGS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired